Synthesis and biological evaluation of loxoprofen derivatives

Naoki Yamakawa, Shintaro Suemasu, Masaaki Matoyama, Ken Ichiro Tanaka, Takashi Katsu, Keishi Miyata, Yoshinari Okamoto, Masami Otsuka, Tohru Mizushima

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) achieve their anti-inflammatory actions through an inhibitory effect on cyclooxygenase (COX). Two COX subtypes, COX-1 and COX-2, are responsible for the majority of COX activity at the gastrointestinal mucosa and in tissues with inflammation, respectively. We previously suggested that both gastric mucosal cell death due to the membrane permeabilization activity of NSAIDs and COX-inhibition at the gastric mucosa are involved in NSAID-induced gastric lesions. We have also reported that loxoprofen has the lowest membrane permeabilization activity among the NSAIDs we tested. In this study, we synthesized a series of loxoprofen derivatives and examined their membrane permeabilization activities and inhibitory effects on COX-1 and COX-2. Among these derivatives, 2-{4′-hydroxy-5-[(2-oxocyclopentyl)methyl]biphenyl-2-yl}propanoate 31 has a specificity for COX-2 over COX-1. Compared to loxoprofen, oral administration of 31 to rats produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 31 is likely to be a therapeutically beneficial and safer NSAID.

Original languageEnglish
Pages (from-to)3299-3311
Number of pages13
JournalBioorganic and Medicinal Chemistry
Volume19
Issue number11
DOIs
Publication statusPublished - 2011 Jun 1
Externally publishedYes

Fingerprint

Anti-Inflammatory Agents
Derivatives
Prostaglandin-Endoperoxide Synthases
Cyclooxygenase 1
Cyclooxygenase 2
Pharmaceutical Preparations
Membranes
Stomach
Gastrointestinal Agents
Propionates
Cell death
Gastric Mucosa
loxoprofen
Oral Administration
Rats
Mucous Membrane
Cell Death
Tissue
Inflammation

Keywords

  • COX-2 specificity
  • Gastric lesions
  • Gastric mucosal cells
  • Loxoprofen
  • Membrane permeabilization

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Yamakawa, N., Suemasu, S., Matoyama, M., Tanaka, K. I., Katsu, T., Miyata, K., ... Mizushima, T. (2011). Synthesis and biological evaluation of loxoprofen derivatives. Bioorganic and Medicinal Chemistry, 19(11), 3299-3311. https://doi.org/10.1016/j.bmc.2011.04.050

Synthesis and biological evaluation of loxoprofen derivatives. / Yamakawa, Naoki; Suemasu, Shintaro; Matoyama, Masaaki; Tanaka, Ken Ichiro; Katsu, Takashi; Miyata, Keishi; Okamoto, Yoshinari; Otsuka, Masami; Mizushima, Tohru.

In: Bioorganic and Medicinal Chemistry, Vol. 19, No. 11, 01.06.2011, p. 3299-3311.

Research output: Contribution to journalArticle

Yamakawa, N, Suemasu, S, Matoyama, M, Tanaka, KI, Katsu, T, Miyata, K, Okamoto, Y, Otsuka, M & Mizushima, T 2011, 'Synthesis and biological evaluation of loxoprofen derivatives', Bioorganic and Medicinal Chemistry, vol. 19, no. 11, pp. 3299-3311. https://doi.org/10.1016/j.bmc.2011.04.050
Yamakawa N, Suemasu S, Matoyama M, Tanaka KI, Katsu T, Miyata K et al. Synthesis and biological evaluation of loxoprofen derivatives. Bioorganic and Medicinal Chemistry. 2011 Jun 1;19(11):3299-3311. https://doi.org/10.1016/j.bmc.2011.04.050
Yamakawa, Naoki ; Suemasu, Shintaro ; Matoyama, Masaaki ; Tanaka, Ken Ichiro ; Katsu, Takashi ; Miyata, Keishi ; Okamoto, Yoshinari ; Otsuka, Masami ; Mizushima, Tohru. / Synthesis and biological evaluation of loxoprofen derivatives. In: Bioorganic and Medicinal Chemistry. 2011 ; Vol. 19, No. 11. pp. 3299-3311.
@article{f09af3ca0c34430ab05f3d3c660c59d1,
title = "Synthesis and biological evaluation of loxoprofen derivatives",
abstract = "Non-steroidal anti-inflammatory drugs (NSAIDs) achieve their anti-inflammatory actions through an inhibitory effect on cyclooxygenase (COX). Two COX subtypes, COX-1 and COX-2, are responsible for the majority of COX activity at the gastrointestinal mucosa and in tissues with inflammation, respectively. We previously suggested that both gastric mucosal cell death due to the membrane permeabilization activity of NSAIDs and COX-inhibition at the gastric mucosa are involved in NSAID-induced gastric lesions. We have also reported that loxoprofen has the lowest membrane permeabilization activity among the NSAIDs we tested. In this study, we synthesized a series of loxoprofen derivatives and examined their membrane permeabilization activities and inhibitory effects on COX-1 and COX-2. Among these derivatives, 2-{4′-hydroxy-5-[(2-oxocyclopentyl)methyl]biphenyl-2-yl}propanoate 31 has a specificity for COX-2 over COX-1. Compared to loxoprofen, oral administration of 31 to rats produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 31 is likely to be a therapeutically beneficial and safer NSAID.",
keywords = "COX-2 specificity, Gastric lesions, Gastric mucosal cells, Loxoprofen, Membrane permeabilization",
author = "Naoki Yamakawa and Shintaro Suemasu and Masaaki Matoyama and Tanaka, {Ken Ichiro} and Takashi Katsu and Keishi Miyata and Yoshinari Okamoto and Masami Otsuka and Tohru Mizushima",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.bmc.2011.04.050",
language = "English",
volume = "19",
pages = "3299--3311",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Synthesis and biological evaluation of loxoprofen derivatives

AU - Yamakawa, Naoki

AU - Suemasu, Shintaro

AU - Matoyama, Masaaki

AU - Tanaka, Ken Ichiro

AU - Katsu, Takashi

AU - Miyata, Keishi

AU - Okamoto, Yoshinari

AU - Otsuka, Masami

AU - Mizushima, Tohru

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Non-steroidal anti-inflammatory drugs (NSAIDs) achieve their anti-inflammatory actions through an inhibitory effect on cyclooxygenase (COX). Two COX subtypes, COX-1 and COX-2, are responsible for the majority of COX activity at the gastrointestinal mucosa and in tissues with inflammation, respectively. We previously suggested that both gastric mucosal cell death due to the membrane permeabilization activity of NSAIDs and COX-inhibition at the gastric mucosa are involved in NSAID-induced gastric lesions. We have also reported that loxoprofen has the lowest membrane permeabilization activity among the NSAIDs we tested. In this study, we synthesized a series of loxoprofen derivatives and examined their membrane permeabilization activities and inhibitory effects on COX-1 and COX-2. Among these derivatives, 2-{4′-hydroxy-5-[(2-oxocyclopentyl)methyl]biphenyl-2-yl}propanoate 31 has a specificity for COX-2 over COX-1. Compared to loxoprofen, oral administration of 31 to rats produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 31 is likely to be a therapeutically beneficial and safer NSAID.

AB - Non-steroidal anti-inflammatory drugs (NSAIDs) achieve their anti-inflammatory actions through an inhibitory effect on cyclooxygenase (COX). Two COX subtypes, COX-1 and COX-2, are responsible for the majority of COX activity at the gastrointestinal mucosa and in tissues with inflammation, respectively. We previously suggested that both gastric mucosal cell death due to the membrane permeabilization activity of NSAIDs and COX-inhibition at the gastric mucosa are involved in NSAID-induced gastric lesions. We have also reported that loxoprofen has the lowest membrane permeabilization activity among the NSAIDs we tested. In this study, we synthesized a series of loxoprofen derivatives and examined their membrane permeabilization activities and inhibitory effects on COX-1 and COX-2. Among these derivatives, 2-{4′-hydroxy-5-[(2-oxocyclopentyl)methyl]biphenyl-2-yl}propanoate 31 has a specificity for COX-2 over COX-1. Compared to loxoprofen, oral administration of 31 to rats produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 31 is likely to be a therapeutically beneficial and safer NSAID.

KW - COX-2 specificity

KW - Gastric lesions

KW - Gastric mucosal cells

KW - Loxoprofen

KW - Membrane permeabilization

UR - http://www.scopus.com/inward/record.url?scp=79957493051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957493051&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2011.04.050

DO - 10.1016/j.bmc.2011.04.050

M3 - Article

C2 - 21570308

AN - SCOPUS:79957493051

VL - 19

SP - 3299

EP - 3311

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 11

ER -